II. Definitions

  1. Tumor Lysis Syndrome
    1. Acute tumor cell lysis post-Chemotherapy or radiation for tumor debulking
    2. Less commonly, tumor lysis may occur spontaneously with inflammatory cancers

III. Pathophysiology

  1. Massive tumor lysis releases breakdown products
    1. Uric Acid (Hyperuricemia)
    2. Phosphate (Hyperphosphatemia)
    3. Calcium (Hypocalcemia)
    4. Potassium (Hyperkalemia)
  2. Tumor breakdown products overwhelm excretion mechanism
    1. Acute Renal Failure (secondary to Hyperuricemia and Calcium Phosphate crystallization)

IV. Risk Factors

  1. Renal Insufficiency
  2. Hematologic Malignancy (esp. Acute Leukemia, high grade Lymphoma)
    1. Less commonly, may occur with solid tumors

V. Causes: Most common associated tumors

  1. Chemotherapy induction (within first 5-7 days)
    1. Less commonly, Radiation Therapy and biologic agents may also cause tumor lysis
  2. Acute presentation of undiagnosed rapidly growing tumor
    1. Acute Lymphocytic Leukemia
    2. Lymphoma
    3. Inflammatory Breast Cancer with high rate of proliferation

VI. Findings: Presentations related Hyperkalemia, Acute Renal Failure

  1. General symptoms
    1. Nausea or Vomiting
    2. Diarrhea
    3. Lethargy
  2. Cardiac findings
    1. Congestive Heart Failure
    2. Dysrhythmia
    3. Syncope
  3. Neurologic findings
    1. Seizures
    2. Muscle cramps
    3. Tetany

VIII. Diagnostics

IX. Diagnosis: Cairo-Bishop Definition

  1. Criteria: Two present in one 24 hour period (3 days before of 7 days after Chemotherapy initiation)
    1. Serum Calcium <=7 mg/dl or 25% decrease from baseline
    2. Serum Phosphorus >=4.5 mg/dl in adults (>6.5 mg/dl children) or 25% increase from baseline
    3. Serum Potassium >=6 mEq/L or 25% increase from baseline
    4. Uric Acid >=8 mg/dl or 25% increase from baseline
  2. Interpretation: Clinical Tumor Lysis Syndrome
    1. Two lab criteria present AND
    2. One of the following
      1. Cardiac arrhythmia or sudden death
      2. Serum Creatinine >= 1.5 times upper limit of normal for age
      3. Seizure Disorder
  3. References
    1. Cairo (2004) Br J Haematol 127(1):3-11 [PubMed]

X. Management

  1. Continuous cardiac monitoring
  2. Hospitalization to intensive care unit at a facility where Hemodialysis and inpatient oncology are available
  3. Consult oncology
  4. Aggressive Intravenous Fluid hydration
    1. Goal urine output: 100 ml/hour
  5. Monitor elecrolytes every 6 hours
    1. Serum electrolytes (Serum Potassium, Renal Function tests, Serum Calcium, Serum Phosphate, serum Uric Acid)
  6. Manage electrolyte abnormalities
    1. See Hyperkalemia Management
    2. See Hypocalcemia
    3. See Hyperuricemia
    4. See Hyperphosphatemia
    5. See Acute Renal Failure
  7. Hyperuricemia management
    1. Rasburicase (Elitek)
      1. Dose: 0.2 mg/kg in 50 ml Normal Saline over 30 minutes daily for 5-7 days
      2. Preferred in moderate to severe tumor lysis
      3. Recombinant form of urate oxidase (uricase) that converts Uric Acid to allantoin
      4. Allantoin is inactive, much more soluble than Uric Acid, and much more easily renally excreted
      5. Contraindicated in G6PD Deficiency (screen high risk populations)
    2. Allopurinol
      1. Blocks nucleic acid metabolism to Uric Acid
      2. Reduces future Uric Acid production
      3. Does NOT affect Uric Acid already produced
        1. Avoid in ill patients (use rasburicase)
  8. Hyperphosphatemia management
    1. Phosphate Binders (e.g. aluminum hydroxide)
    2. Hemodialysis
  9. Hyperkalemia Management
    1. See Hyperkalemia
  10. Hypocalcemia management
    1. Hypocalcemia is secondary to Hyperphosphatemia
    2. Do not start Calcium Replacement unless Hyperphosphatemia has corrected
      1. Risk of increased Calcium Phosphate crystals and worsening Acute Renal Failure
      2. Exceptions (in which cases calcium administration is indicated
        1. Hypocalcemia related complications (e.g. Seizures, CHF)
        2. Hyperkemia related EKG changes
  11. Alkalinize urine in not recommended in most cases
    1. Not routinely recommended
  12. Hemodialysis
    1. See Hemodialysis for indications

XI. Prevention

  1. Anticipate Tumor Lysis Syndrome
    1. Pretreatment with Intravenous hydration and maintain adequate urine output
    2. Pretreatment with Allopurinol to reduce baseline serum Uric Acid levels
    3. Pretreatment - limit intake of Potassium and phosphorus (3 days before and 7 days after initiation)

XII. References

  1. Aurora and Herbert in Majoewsky (2013) EM:Rap 13(10): 1-4
  2. Shelby (2015) Crit Dec Emerg Med 29(6): 2-8
  3. Higdon (2006) Am Fam Physician 74:1873-80 [PubMed]
  4. Higdon (2018) Am Fam Physician 97(11):741-8 [PubMed]
  5. Zuckerman (2012) Blood 120(10): 1993-2002 [PubMed]

Images: Related links to external sites (from Bing)

Related Studies (from Trip Database) Open in New Window

Ontology: Tumor Lysis Syndrome (C0041364)

Definition (NCI_CTCAE) A disorder characterized by metabolic abnormalities that result from a spontaneous or therapy-related cytolysis of tumor cells.
Definition (NCI_NCI-GLOSS) A condition that can occur after treatment of a fast-growing cancer, especially certain leukemias and lymphomas (cancers of the blood). As tumor cells die, they break apart and release their contents into the blood. This causes a change in certain chemicals in the blood, which may cause damage to organs, including the kidneys, heart, and liver.
Definition (NCI) A condition of metabolic abnormalities that result from a spontaneous or therapy-related cytolysis of tumor cells. Tumor lysis syndrome typically occurs in aggressive, rapidly proliferating lymphoproliferative disorders. Burkitt lymphoma and T cell acute lymphoblastic leukemia are commonly associated with this syndrome. Metabolic abnormalities include hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia and may result in renal failure, multiple organ failure, and death.
Definition (MSH) A syndrome resulting from cytotoxic therapy, occurring generally in aggressive, rapidly proliferating lymphoproliferative disorders. It is characterized by combinations of hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia.
Concepts Disease or Syndrome (T047)
MSH D015275
ICD9 277.88
ICD10 E88.3
SnomedCT 277605001
English Syndrome, Tumour Lysis, Syndromes, Tumor Lysis, Syndromes, Tumour Lysis, Tumor Lysis Syndromes, Tumour Lysis Syndrome, Tumour Lysis Syndromes, Syndrome, Tumor Lysis, TUMOUR LYSIS SYNDROME, TUMOR LYSIS SYNDROME, Tumor Lysis Syndrome, Tumor Lysis Syndrome [Disease/Finding], tumour lysis syndrome, tumor lysis syndrome (diagnosis), Tumor lysis syndrome, Tumour lysis syndrome, Tumor lysis syndrome (disorder), tumor lysis syndrome
Portuguese SINDROME DE LISE TUMORAL, Síndrome de lise tumoral, Síndrome de Lise Tumoral
Italian Sindrome da lisi tumorale, Sindrome da lisi di cellule tumorali
Spanish Síndrome de lisis tumoral, síndrome de lisis tumoral (trastorno), síndrome de lisis tumoral, Síndrome de lisis del tumor, Síndrome de Lisis Tumoral
Swedish Tumörlyssyndrom
Japanese シュヨウホウカイショウコウグン, 腫瘍融解症候群, 腫瘍崩壊症候群, 腫瘍溶解症候群
Czech syndrom lýzy nádoru, Syndrom nádorového rozpadu
Finnish Tuumorilyysioireyhtymä
Russian NOVOOBRAZOVANIIA RASPADA SINDROM, НОВООБРАЗОВАНИЯ РАСПАДА СИНДРОМ
French SYNDROME DE LYSE TUMORALE, Syndrome de lyse tumorale
German TUMORLYSESYNDROM, Tumorlysesyndrom, Tumorlyse-Syndrom
Polish Zespół lizy nowotworu
Hungarian Tumor lysis syndroma
Norwegian Tumorlysesyndrom, Tumorlyse, Tumor lysissyndrom
Dutch tumorlysissyndroom, Syndroom, tumorlysis-, Tumorlysissyndroom